Title:
METHOD FOR TREATING PRIMARY AXILLARY HYPERHIDROSIS AND PHARMACEUTICAL PRODUCT THEREFOR
Document Type and Number:
WIPO Patent Application WO/2021/177257
Kind Code:
A1
Abstract:
Disclosed is a pharmaceutical preparation to be applied once a day to both axillae and comprising sofpironium bromide as an active ingredient, the preparation being for treating primary axillary hyperhidrosis wherein the overall bilateral-axillary gravimetric sweat production measured according to the gravimetric method for five minutes before treatment is 400 mg or greater.
Inventors:
KODERA NOBUYUKI (JP)
YOROZUYA TOSHIYUKI (JP)
AKAMATSU MOTOKI (JP)
OTANI IPPEI (JP)
ISEKI HIROSHI (JP)
ONO AKIHIRO (JP)
TSUBOI DAIKI (JP)
NISHIHARA YUKI (JP)
YOROZUYA TOSHIYUKI (JP)
AKAMATSU MOTOKI (JP)
OTANI IPPEI (JP)
ISEKI HIROSHI (JP)
ONO AKIHIRO (JP)
TSUBOI DAIKI (JP)
NISHIHARA YUKI (JP)
Application Number:
PCT/JP2021/007791
Publication Date:
September 10, 2021
Filing Date:
March 02, 2021
Export Citation:
Assignee:
KAKEN PHARMA CO LTD (JP)
International Classes:
A61K31/40; A61K9/08; A61K47/08; A61K47/10; A61K47/12; A61K47/14; A61K47/32; A61K47/34; A61K47/38; A61P1/02; A61P9/00; A61P11/00; A61P11/06; A61P13/10; A61P17/00; A61P25/02; A61P27/02
Foreign References:
| JP2018520198A | 2018-07-26 |
Other References:
KIRSCH BRANDON, SMITH STACY, COHEN JOEL, DUBOIS JANET, GREEN LAWRENCE, BAUMANN LESLIE, BHATIA NEAL, PARISER DAVID, LIU PING-YU, CH: "Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 82, no. 6, February 2020 (2020-02-01), pages 1321 - 1327, XP055852291
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF: